Dempze Nancy E boosted its position in shares of Novartis AG (NYSE:NVS) by 7.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,696 shares of the company’s stock after purchasing an additional 1,244 shares during the period. Novartis AG makes up 2.1% of Dempze Nancy E’s holdings, making the stock its 19th biggest holding. Dempze Nancy E’s holdings in Novartis AG were worth $1,521,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. CGOV Asset Management raised its stake in shares of Novartis AG by 2.5% in the 1st quarter. CGOV Asset Management now owns 997,161 shares of the company’s stock valued at $98,662,000 after acquiring an additional 24,430 shares during the period. Vident Investment Advisory LLC grew its holdings in Novartis AG by 19.0% during the 1st quarter. Vident Investment Advisory LLC now owns 12,457 shares of the company’s stock worth $925,000 after acquiring an additional 1,992 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its holdings in Novartis AG by 2.1% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 1,664,465 shares of the company’s stock worth $123,921,000 after acquiring an additional 33,818 shares in the last quarter. AE Wealth Management LLC grew its holdings in Novartis AG by 79.1% during the 1st quarter. AE Wealth Management LLC now owns 10,172 shares of the company’s stock worth $755,000 after acquiring an additional 4,493 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new position in Novartis AG during the 1st quarter worth approximately $18,959,000. 11.00% of the stock is currently owned by institutional investors.
Several analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 price objective for the company in a research report on Tuesday, September 19th. Morgan Stanley upgraded shares of Novartis AG from an “underweight” rating to an “overweight” rating in a research report on Wednesday, July 26th. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a research report on Tuesday, October 24th. Barclays PLC downgraded shares of Novartis AG from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Finally, BidaskClub upgraded shares of Novartis AG from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $85.32.
Shares of Novartis AG (NYSE:NVS) opened at $82.71 on Wednesday. The firm has a market cap of $194,877.70, a P/E ratio of 17.34, a PEG ratio of 2.63 and a beta of 0.72. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. Novartis AG has a 1 year low of $66.93 and a 1 year high of $86.90.
Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.04. Novartis AG had a net margin of 13.73% and a return on equity of 15.77%. The firm had revenue of $12.41 billion during the quarter, compared to the consensus estimate of $12.21 billion. During the same quarter in the previous year, the company posted $1.23 earnings per share. The firm’s revenue was up 2.4% on a year-over-year basis. research analysts expect that Novartis AG will post 4.75 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Dempze Nancy E Increases Stake in Novartis AG (NYSE:NVS)” was first published by Week Herald and is owned by of Week Herald. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://weekherald.com/2017/11/15/novartis-ag-nvs-shares-bought-by-dempze-nancy-e.html.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.